Leuprolide is a gonadotropin releasing hormone agonist used for patients with prostate cancer and a variety of gynecologic diseases, such as uterine myoma, endometriosis, and adenomyosis. Reported side effects include a local skin eruptions, anaphylactoid reactions, ischemic heart diseases, and seizures.
INTRODUCTION
Leuprolide is a gonadotropin releasing hormone (GnRH) agonist that desensitizes GnRH receptor. Accordingly, Leuprolide decreases the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Also, Leuprolide suppresses production of gonadal sex hormone. Leuprolide is used to treat various diseases, such as prostate cancer, uterine myoma, endometriosis, and central precocious puberty. 1 Adverse effects from the use of leuprolide have been reported. They range from local skin irritation to severe anaphylactoid reactions. 2 Related to cardiac adverse effects, several cases of angina and ischemic heart diseases have been reported from the patients with the history of being treated with leuprolide. 3 months after the discharge showed that the previous lesion was partially resolved (Fig. 3) .
DISCUSSION
PRES is defined as a clinicoradiological entity characterized by neurologic symptoms, which include headache, vomiting, altered mental status, blurred vision, and seizures. Typically, cranial MR images suggest vasogenic edema which mainly involve posterior regions of the brain. PRES is known to be related to a hypertensive state of Ischemic heart diseases are well documented in patients treated with leuprolide. 3 Since estrogen is known to have cardioprotective effects, hypogonadism induced by GnRH agonist explains the prevalence of ischemic heart diseases in otherwise healthy premenopausal women with no other risk factors. 10 Since ischemic heart diseases and cerebrovascular accidents share common risk factors, it is reasonable to infer that leuprolide might play a role in the development of PRES as well.
In conclusion, leuprolide can be a rare cause of PRES.
Therefore, clinical suspicion of PRES should be raised when new onset of headache, visual disturbance, or seizure occurs in patients who have a history of treatment with leuprolide.
